Maximum quantity allowed is 999
Please select the quantity
CAS RN: 66898-62-2 | Product Number: T3101
Talniflumate
×
![]()
×
Purity: >98.0%(HPLC)(N)
Synonyms:
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 200MG |
$86.00
|
14 | 22 | It can be shipped in about 2 weeks after ordering | |
| 1G |
$283.00
|
0 | 20 | It can be shipped in about 2 weeks after ordering |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | T3101 |
Purity / Analysis Method 
|
>98.0%(HPLC)(N) |
| Molecular Formula / Molecular Weight | C__2__1H__1__3F__3N__2O__4 = 414.34 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 66898-62-2 |
| Reaxys Registry Number | 503261 |
| PubChem Substance ID | 253662062 |
| Merck Index (14) | 9044 |
| MDL Number | MFCD00866135 |
Specifications
| Appearance | White to Yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 98.0 % |
| Melting point | 166.0 to 170.0 °C |
Properties (reference)
| Melting Point | 168 °C |
| Maximum Absorption Wavelength | 287 nm (CHCl__3) |
GHS
Related Laws:
| RTECS# | QT2999200 |
Transport Information:
| H.S.code* | 2933.39-000 |
Application
Talniflumate: An Inhibitor of Human Calcium-Activated Chloride Channels
Talniflumate, also known as MSI-1995, is an inhibitor of human calcium-activated chloride channels. It is a prodrug of niflumic acid [T2353]. It was originally developed as an anti-inflammatory agent, but is currently being developed as a mucous regulator for the treatment of cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and asthma. (The product is for research purpose only.)
References
- Pharmacokinetics of talniflumate, a prodrug of niflumic acid, following oral administration to man
- Talniflumate (Genaera) (a review)
- D. Knight, Curr. Opin. Invest. Drugs 2004, 5, 557.
- Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome
- Effect of food on systemic exposure to niflumic acid following postprandial administration of talniflumate
- Simultaneous determination of niflumic acid and its prodrug, talniflumate in human plasma by high performance liquid chromatography
PubMed Literature
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.